Lv1
57 积分 2025-03-06 加入
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study
9天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1个月前
已完结
Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes
2个月前
已完结
Prevalence and Trend of Biopsy-Proven IgA Nephropathy in China: A Systematic Review
4个月前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
5个月前
已完结
Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults
5个月前
已完结
Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti‐Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions
5个月前
已完结
皖公网安备34019202002308
